Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Beáta, Gasztonyi"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Beáta Gasztonyi, Lajos Varga-Szabo, Laszlo Lakatos, Ferenc Izbéki, Árpád V. Patai, Livia Lontai, Peter L. Lakatos, Akos Ilias, Lorant Gonczi, István Rácz
Publikováno v:
Journal of Gastrointestinal and Liver Diseases. 30:327-333
Background and Aims: Acute non-variceal upper gastrointestinal bleeding (UGIB) is associated with significant morbidity and mortality. Our aim was to evaluate the incidence, management, risk factors and outcomes of acute non-variceal UGIB in a popula
Autor:
Peter L. Lakatos, Ferenc Izbéki, Lajos Varga-Szabo, István Rácz, Beáta Gasztonyi, Laszlo Lakatos, Lorant Gonczi, Árpád V. Patai, Akos Ilias, Ádám Barnabás
Publikováno v:
Orvosi Hetilap. 162:1252-1259
Összefoglaló. Bevezetés: Az akut varixeredetű gastrointestinalis vérzés napjainkban is jelentős morbiditással és mortalitással jár. Célkitűzés: Célunk az akut varixeredetű felső gastrointestinalis vérzések incidenciájának, ellát
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pál Miheller, Karin Malíčková, Ágnes Milassin, Tamas Szamosi, Zoltán Szepes, Katarina Mitrova, Milan Lukas, Krisztina Gecse, Zsuzsanna Kurti, Árpád V. Patai, Martin Kolar, Áron Vincze, Anita Bálint, Zsuzsanna Vegh, Klaudia Farkas, Károly Palatka, Peter L. Lakatos, Martin Bortlik, Anna Fábián, Dana Duricova, Laszlo Lakatos, László Bene, Tunde Kristof, Ferenc Nagy, Beáta Gasztonyi, Gábor Tamás Tóth, Renáta Bor, Ágnes Salamon, János Banai, Veronika Hruba, Tamás Molnár, Martin Lukas, Mariann Rutka
Publikováno v:
Expert opinion on drug safety, 16(8), 885-890. Taylor and Francis Ltd.
Background: Safety data of the ‘real life’ use of an infliximab biosimilar, CT-P13 in inflammatory bowel disease (IBD) are still lacking. Our aim was to assess the frequency and characteristics of infusion reactions during CT-P13 therapy in 13 Hu
Publikováno v:
Orvosi Hetilap. 157:869-872
The authors present the case history of a patient suffering from hyperthyroidism. The diagnostic procedures revealed the presence of propylthiouracyl induced vasculitis with renal involvement, that recovered completely after the withdrawal of propylt
Autor:
Beáta Gasztonyi, Ágnes Salamon, Tamas Szamosi, Zsuzsanna Vegh, Petra A. Golovics, Zsuzsanna Kurti, Edina Bíró, Zoltán Szepes, Mariann Rutka, Áron Vincze, Laszlo Lakatos, Károly Palatka, Árpád V. Patai, Pál Miheller, Gábor Tamás Tóth, László Bene, Lorant Gonczi, Klaudia Farkas, Krisztina Gecse, Mária Papp, Tunde Kristof, Tamás Molnár, Renáta Bor, Peter L. Lakatos, Barbara D. Lovasz
Publikováno v:
Journal of Crohn's and Colitis, 11(6), 697-705. Elsevier
Background and Aims: Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator product. In the present study, we aimed to evaluate the predictors of short- and medium-term clinic
Autor:
Árpád V. Patai, Zsuzsanna Vegh, Laszlo Lakatos, Zsuzsanna Kurti, László Bene, Beáta Gasztonyi, Ágnes Salamon, Balázs Szalay, Tamas Szamosi, János Banai, Mariann Rutka, Tamás Molnár, Mária Papp, Pál Miheller, Klaudia Farkas, Krisztina Gecse, Zoltán Szepes, Peter L. Lakatos, Gábor Tamás Tóth, Tunde Kristof, Ferenc Nagy, Áron Vincze, Károly Palatka, Barbara D. Lovasz, Lorant Gonczi, Petra A. Golovics
Publikováno v:
Inflammatory bowel diseases, 23(11), 1908-1915. John Wiley and Sons Inc.
Background: It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission in inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide inflammatory bowel disease cohort.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d036a098c5d7e82f0d9aeb84df20c04c
https://pure.amc.nl/en/publications/longterm-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort(c4986fb7-037f-4289-a195-61ac4f749e98).html
https://pure.amc.nl/en/publications/longterm-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort(c4986fb7-037f-4289-a195-61ac4f749e98).html
Autor:
Márta Erzsébet Vinkler, György Tüske, Márta Széll, Mária Szenes, Gyula Herr, Györgyi Hohl, Mariann Tihanyi, Gyöngyi Nagy, Beáta Gasztonyi, János Horváth, Nikoletta Nagy
Publikováno v:
Orvosi Hetilap. 156:979-984
Muir–Torre syndrome is a rare genodermatosis with autosomal dominant inheritance. The syndrome is considered to be a subtype of the hereditary nonpolyposis colorectal cancer (or Lynch-syndrome). In two-third of the cases, it develops as the consequ
Publikováno v:
Open Journal of Obstetrics and Gynecology. :75-80
AIM: The authors have aimed at confirming or excluding gluten sensitivity in infertile couples. PATIENTS AND METHODS: Between 2004 and 2010, at our outpatient clinics of immunology, both partners of 223 couples, who had striven for having a child uns